News
The stock's fall snapped a two-day winning streak.
Shares of Regeneron Pharmaceuticals Inc. rallied 3.36% to $591.01 Wednesday, on what proved to be an all-around mixed trading ...
16h
TipRanks on MSNRegeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer?
Intellia Therapeutics Inc ((NTLA)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools ...
The hits just keep on coming for Regeneron’s Eylea franchise. | The FDA has extended its target action dates for two ...
Regeneron Pharmaceuticals announced FDA extended review timelines to Q4 2025 for two regulatory submissions related to Eylea ...
The delays, first revealed in Regeneron’s Q2 report, were chalked up to manufacturing issues at Novo Nordisk-owned plants.
Johnson & Johnson said on Thursday it would invest $2 billion in North Carolina as it aims to expand its U.S. manufacturing ...
1d
Pharmaceutical Technology on MSNNovo’s facility issues delay FDA decisions on Regeneron’s Eylea HD
Before Novo arrived as its owner, issues at the Bloomington facility caused a two-month delay for Eylea HD’s FDA approval ...
A hedge fund run by legendary investor Michael Burry kicked off a new $383 million bullish bet split between four different ...
The FDA has identified critical lapses at a production facility operated by Novo Nordisk that is used by several drugmakers, ...
Despite boasting a new owner, the Indiana manufacturing plant that Novo Nordisk picked up as part of its parent company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results